Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Study of Patients With Human Papillomavirus-positive Recurrent/ Metastatic Oropharyngeal Squamous Cell Carcinoma Treated With First Line Pembrolizumab or Nivolumab With or Without Chemotherapy

NCT06771674 is registered in ClinicalTrials.gov with Hookipa Biotech GmbH as lead sponsor.

NCT NCT06771674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06771674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Study of Patients With Human Papillomavirus-positive Recurrent/ Metastatic Oropharyngeal Squamous Cell Carcinoma Treated With First Line Pembrolizumab or Nivolumab With or Without Chemotherapy
Lead sponsor
Hookipa Biotech GmbH
Phase
Observational
Overall status
Completed
Start date
June 5, 2024
Completion date
February 28, 2025
Enrollment
662 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oropharyngeal squamous cell carcinoma